High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
about
Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience.High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma.Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoTreatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients.Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions.Treatment approaches for primary CNS lymphomas.Primary central nervous system lymphoma: implication of high-dose chemotherapy followed by auto-SCTPrimary CNS lymphoma: a clinician's guide.Management of elderly patients with primary central nervous system lymphoma.Diagnosis and treatment of primary CNS lymphoma.Current uses of radiation therapy in patients with primary CNS lymphoma.Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma.The role of radiation therapy in the management of primary central nervous system lymphoma.Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom.High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B‑cell lymphoma with secondary central nervous system involvement.Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant.Current and emerging pharmacotherapies for primary CNS lymphoma.Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma.Remobilization of hematopoietic stem cells with high-dose methotrexate and cytarabine in patients with non-Hodgkin's lymphoma and multiple myeloma after failure to mobilize with chemotherapy and cytokines.High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation.Role of radiation therapy in primary central nervous system lymphoma : KROG 14-20 Collaborative Study of Brain and Lymphoma Committee.Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience.High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience.Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission.Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
P2860
Q33413754-5F88D848-B030-43D7-B31A-4EC461988C7CQ33626490-22A2EC4E-A0D7-44F3-B7E6-3FF430CDCF25Q34190457-318B6E58-5E38-4ECF-9F4A-5952979C0A29Q34943963-96E69E62-52F2-4746-9811-BD6247BFF796Q35959919-4B92F489-7BC9-4E7F-8426-006AE883DEC2Q37021529-D9383D50-C3AD-4046-97DB-7F19B0826669Q37330176-879494DD-74E9-49F9-9416-459C45A9CDBDQ37739428-06F8521D-DA23-49FD-9EFF-9B5224EE9312Q37946249-AEACB029-82ED-46E8-8236-581D7DE9F490Q38053442-96BF8B19-B96E-4D63-8975-591E08023C98Q38096927-7AEE3ACD-AB53-4151-A675-E0CCDC8509E6Q38106613-52E63D37-2770-4CDC-9698-6CB3A1841195Q38154956-71D8116B-58D1-4462-BF25-EED7050A4530Q38184642-02B82F38-E91A-497E-9469-B7760EBA3D83Q38248968-3ECC2609-08D0-4827-911C-8DB2D57EA6EAQ38302642-8E86C27F-31F5-4CC7-82D0-74E7392D5F7EQ38743903-4D06654E-3928-49FC-850C-517470FC591CQ38859813-FBE5FA43-B0B8-4A40-84D4-50A812FF58DBQ39005626-7D6286D3-7B3F-4B70-BD9A-B89B96402D04Q41192714-DD03A9EF-55F5-4DE4-BB42-B770850A94ABQ41276228-B970E65D-15B3-42E8-ADDE-A4FCF61306E0Q42126754-7908AFDF-3B8E-4859-BB9D-59E72E712DB4Q42211225-6751401D-EBAB-464B-882E-E2ACB0D55AAEQ43860084-2C2A277B-6ACF-4B78-98BB-3C886C71904BQ45001844-F5286BB6-F44C-4290-9B19-76E462441E8FQ48100638-3E6410E5-43A4-448E-8B7E-FCFDA737F281Q48240328-E2E22F70-03E7-45BC-AA03-54B0749A2789Q48429596-9B4EF8CE-EB43-4DD3-866B-6B4F62320B4AQ48823168-8CD60277-C04B-497F-89B5-DEABCD8D8116Q49790702-517DFBE5-F346-4F84-BB19-151433517F1BQ51295662-B331AD19-8831-4571-A18B-A52B69A79A38
P2860
High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
High-dose thiotepa, busulfan, ...... rognosis primary CNS lymphoma.
@en
High-dose thiotepa, busulfan, ...... rognosis primary CNS lymphoma.
@nl
type
label
High-dose thiotepa, busulfan, ...... rognosis primary CNS lymphoma.
@en
High-dose thiotepa, busulfan, ...... rognosis primary CNS lymphoma.
@nl
prefLabel
High-dose thiotepa, busulfan, ...... rognosis primary CNS lymphoma.
@en
High-dose thiotepa, busulfan, ...... rognosis primary CNS lymphoma.
@nl
P2093
P2860
P356
P1476
High-dose thiotepa, busulfan, ...... rognosis primary CNS lymphoma.
@en
P2093
Chaudhry A
Russell JA
Stewart DA
P2860
P2888
P304
P356
10.1038/SJ.BMT.1703917
P407
P577
2003-04-01T00:00:00Z